Health Solutions

Pharmaceuticals

Section 1

Overview

Pharmaceuticals overview

Rapid changes in the pharmaceutical and drug development fields require a dedicated team of experts. Our consulting experience includes applying actuarial principles to health economics challenges for both pharmaceuticals and medical devices and builds on the support of in-house health economists and clinicians. Our areas of research draw on real-world evidence and outcomes data.

Section 2

INSIGHT

Milliman pharmaceuticals insight

Article

Actuarial approaches to modelling and mitigating financial uncertainty in recommending new drugs and health technologies

In collaboration with the National Institute for Health and Care Excellence (NICE) in England, we explore some alternative methodological approaches that build on the incremental cost-effectiveness ratio.

Download PDF

Presentation

Can we use insurance-based reimbursement models for novel antibiotics?

We explore how the principles of insurance can be applied to structure reimbursement models for novel antibiotics, and ultimately stimulate innovation while offering financial protection to payers.

Download PDF

Research Report

Evaluating payment models for high-cost curative therapies

A research report that evaluates alternative payment models that potentially could be instituted by healthcare payers and manufacturers to pay for high-cost curative disease therapies and prescription drugs.

Read the article

Article

Genomic testing: Cost-savings or cost-inflating for payers

The rapid uptake of genetic testing within the National Health Service (NHS) and current debate around genetics make evaluating tailored interventions increasingly more relevant to ensure an efficient use of NHS spend.

Read the article

Interview

U.K.'s NICE sheds light on comparative value

The National Institute for Health and Clinical Excellence in England offers an interesting model for healthcare reform. We asked Joanne Buckle for her perspective.

Read the article

Section 3

Milliman Inpatient Benchmarking Tool

Milliman's Inpatient Benchmarking Tool is designed to help public health systems like the NHS make better use of their limited resources. The tool aims to reflect an absolute standard of care of what is possible to achieve given optimal infrastructure and best practice care.

Learn more

Products

Milliman pharmaceuticals products

Healthcare cost modelling

Health Cost Guidelines Suite

Estimate expected claims costs and model healthcare utilisation with Milliman’s Health Cost Guidelines™, an industry gold standard.

Learn more

Healthcare risk adjustment

Milliman Advanced Risk Adjusters

Fuel population health analytics and manage risk adjustment with our award-winning suite of tools and data.

Learn more

Financial Modeling Platform with Excel language

Milliman MIND

Milliman Mind is a flexible and easy-to-use web-based platform which automatically converts Excel spreadsheets into more powerful models.

Learn more

Section 4

Services

Solutions

Topics

Solutions

Topics

Solutions

Topics

Careers

About

Health Solutions

Pharmaceuticals

Pharmaceuticals overview

Milliman pharmaceuticals insight

Actuarial approaches to modelling and mitigating financial uncertainty in recommending new drugs and health technologies

Can we use insurance-based reimbursement models for novel antibiotics?

Evaluating payment models for high-cost curative therapies

Genomic testing: Cost-savings or cost-inflating for payers

U.K.'s NICE sheds light on comparative value

Milliman Inpatient Benchmarking Tool

Milliman pharmaceuticals products

Health Cost Guidelines Suite

Milliman Advanced Risk Adjusters

Milliman MIND

Milliman pharmaceuticals services

Actuarial consulting: Healthcare

Benchmarking

Enterprise risk management

Contract analysis

Strategic financial planning

We’re here to help

We’re here to help

CHOOSE A LOCATION AND LANGUAGE